Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guihuang Qingre Granules is a traditional Chinese medicine (TCM) developed and manufactured by Hainan Star Pharmaceutical. Administered orally, it is primarily indicated for the treatment of 'wind-heat' type common colds, which are typically characterized by symptoms such as fever, headache, sore throat, and cough. The formulation is designed to 'clear heat' and 'detoxify' according to traditional Chinese medical principles. As a TCM product, its therapeutic effects are derived from a multi-component herbal mixture, which includes ingredients such as Cinnamomi Ramulus (Guizhi) and Scutellariae Radix (Huangqin), known for their anti-inflammatory and antipyretic properties. The product is approved for marketing in China and is part of Hainan Star Pharmaceutical's portfolio of respiratory treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on guihuang qingre granules.